said Thursday that fourth-quarter profit rose 73%, matching analysts' forecasts, fueled by surging sales of cancer drugs Rituxan and Herceptin. Genentech said net income in the quarter ended Dec ...

I Want So Much to Live, a 2009 documentary about the genesis of Genentech’s breast cancer drug Herceptin, offers a wealth of detail about the discovery and development challenges faced by makers of ...

In the PHranceSCa study, Genentech is currently investigating patient preference for SC administration of the FDC compared to standard IV administration of Perjeta and Herceptin in people with ...

BOSTON (MarketWatch) -- Genentech said Wednesday it has applied to U.S. regulators to have its breast cancer drug Herceptin approved to treat early-stage breast cancer. According to the company ...

A new study has shown that heart failure risk does not increase over time among patients who take Genentech's breast cancer drug Herceptin, the company announced Sunday. Approximately 4.1% of ...

Genentech Inc. prevailed over Chiron Corp. on Friday in a patent dispute concerning rights to one of Genentech’s best-selling medicines, the breast cancer drug Herceptin. A federal court jury in ...

In the fourth quarter, Genentech will continue to enjoy easy year-over-year comparisons and outsized gains in its Avastin and Herceptin product lines. These products began to experience expanded ...

SAN FRANCISCO (CBS.MW) -- Genentech and Wyeth Pharmaceuticals said late Thursday they had entered a manufacturing agreement for Herceptin, Genentech's treatment for HER2-positive metastatic breast ...

Genentech's Herceptin announcement also breaks new medical and scientific ground. When the biotech giant won approval for Herceptin in 1998, the company agreed to test breast cancer patients to ...